Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
allium cepa + heparin + allantoin is a topical combination drug primarily marketed under the brand name Contractubex for the treatment of various types of scars. The formulation combines the anti-inflammatory and anti-proliferative properties of Allium cepa (onion extract), which inhibits fibroblast activity and collagen synthesis, with the anti-thrombotic and anti-inflammatory effects of heparin, which helps soften the collagen structure. Allantoin provides a keratolytic effect that promotes wound healing and enhances the skin's ability to bind water, which improves the penetration of the other active ingredients and relieves itching. This synergistic combination is indicated for hypertrophic scars, keloids, and movement-restricting scars resulting from surgery, burns, or trauma.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on allium cepa + heparin + allantoin.